In the treatment of clinical obesity, preclinical outcomes of adiposity remain critical to advancing the right drug candidate. However, there is much more to it than the scale.
Charles River now offers purpose-bred isolator-reared animal models that make the ideal sentinel for use in your research animal health surveillance programs.
Charles River has been supporting the development of new vaccines and drugs to protect against deadly diseases for decades. And now, more than ever, our scientific experts are working together with our sponsors to accelerate this research.
Charles River has recently added four new ÄKTA™ avant chromatography units to the existing selection of chromatography equipment at our viral clearance facility located in King of Prussia, PA, USA. This recent investment provides additional capacity for the execution of viral clearance studies at Charles River.
By tapping into our scientific excellence and regulatory knowledge, you get cost-effective, fully integrated programs tailored to your specific needs. Our scientific program managers leverage our full range of services and best-in-class expertise to design your optimum program and ensure that it is completed on time and within budget.
Charles River is pleased to announce the addition of a workspace dedicated to GMP-compliant in vivo potency/immunopotency testing at our in vivo biosafety testing facility in Wilmington, MA, USA.
Advances in our understanding of the role of cardiac ion channels in arrhythmogenesis, and newly available in vitro technologies, has prompted implementation of a new strategy for identifying cardiac risk during drug development.
For translatability into the clinic, our inhalation team has developed systems that allow sufficient delivery of respirable aerosol in order to achieve the higher dose levels necessary for preclinical trials.
In vitro antibody-dependent cellular phagocytosis (ADCP) assays based on primary macrophages as effector cells are excellent tools to establish the in vivo mechanism of action (MOA) of a therapeutic monoclonal antibody (mAb) during the early phase of drug development.
Charles River is pleased to announce that our 2015 Research Models and Services catalog is now available electronically.